Evidence map›Paper›PMID 30619907›Full record

ArticleOpen forum infectious diseases2018

Clinical Features, Severity, and Incidence of RSV Illness During 12 Consecutive Seasons in a Community Cohort of Adults ≥60 Years Old.

Edward A Belongia, Jennifer P King, Burney A Kieke, Joanna Pluta, Ali Al-Hilli, Jennifer K Meece, Vivek Shinde

Abstract read
PubMed Full text at PMC Publisher
In one paragraph

Article in Open forum infectious diseases, 2018. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 105 papers, 6 of them syntheses that pooled it.

0numbers the graph read from it
0cells of the map it votes in
105citing papers in PubMed, 6 pooled it
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

105 citing papers in PubMed, 6 syntheses or guidelines pooled it.

  1. Pooled it
  2. Pooled it
  3. Pooled it
  4. Pooled it
  5. Pooled it
  6. Systematic review on respiratory syncytial virus epidemiology in adults and the elderly in Latin America.International journal of infectious diseases : IJID : official publication of the International Society for Infectious Diseases · 2020
    Pooled it
  7. Trial
  8. Efficacy and Safety of Respiratory Syncytial Virus (RSV) Prefusion F Protein Vaccine (RSVPreF3 OA) in Older Adults Over 2 RSV Seasons.Clinical infectious diseases : an official publication of the Infectious Diseases Society of America · 2024
    Trial
  9. Trial
  10. Article
  11. Observational
  12. Article
  13. Health-related Quality of Life in European Older Adults with Respiratory Syncytial Virus Over Three Respiratory Syncytial Virus Seasons.Clinical infectious diseases : an official publication of the Infectious Diseases Society of America · 2026
    Article
  14. Observational
  15. Review
  16. Article
  17. Article
  18. Article
  19. Article
  20. Observational

45 more citing papers are in PubMed but not listed here.

4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

7 authors.

Edward A BelongiaMarshfield Clinic Research Institute, Marshfield, Wisconsin.
Jennifer P KingMarshfield Clinic Research Institute, Marshfield, Wisconsin.
Burney A KiekeMarshfield Clinic Research Institute, Marshfield, Wisconsin.
Joanna PlutaMarshfield Clinic Health System, Marshfield, Wisconsin.
Ali Al-HilliMarshfield Clinic Health System, Marshfield, Wisconsin.
Jennifer K MeeceMarshfield Clinic Research Institute, Marshfield, Wisconsin.
Vivek ShindeNovavax, Inc., Gaithersburg, Maryland.

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

backgroundThe epidemiology and burden of respiratory syncytial virus (RSV) illness are not well defined in older adults.

methodsAdults ≥60 years old seeking outpatient care for acute respiratory illness were recruited from 2004-2005 through 2015-2016 during the winter seasons. RSV was identified from respiratory swabs by multiplex polymerase chain reaction. Clinical characteristics and outcomes were ascertained by interview and medical record abstraction. The incidence of medically attended RSV was estimated for each seasonal cohort.

resultsRSV was identified in 243 (11%) of 2257 enrollments (241 of 1832 individuals), including 121 RSV type A and 122 RSV type B. The RSV clinical outcome was serious in 47 (19%), moderate in 155 (64%), and mild in 41 (17%). Serious outcomes included hospital admission (n = 29), emergency department visit (n = 13), and pneumonia (n = 23) and were associated with lower respiratory tract symptoms during the enrollment visit. Moderate outcomes included receipt of a new antibiotic prescription (n = 144; 59%), bronchodilator/nebulizer (n = 45; 19%), or systemic corticosteroids (n = 28; 12%). The relative risk of a serious outcome was significantly increased in persons aged ≥75 years (vs 60-64 years) and in those with chronic obstructive pulmonary disease or congestive heart failure. The average seasonal incidence was 139 cases/10 000, and it was significantly higher in persons with cardiopulmonary disease compared with others (rate ratio, 1.89; 95% confidence interval, 1.44-2.48).

conclusionsRSV causes substantial outpatient illness with lower respiratory tract involvement. Serious outcomes are common in older patients and those with cardiopulmonary disease.

Indexed as

adultepidemiologyincidenceoutcomesRSV

Identifiers

PMID30619907
PMCPMC6306566

What OpenQuestion holds

Textmetadata
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.